José Luis
Pérez Gracia
Consultor Médico
Luis Alfonso
Gurpide Ayarra
Consultor Médico
Publications dans lesquelles il/elle collabore avec Luis Alfonso Gurpide Ayarra (34)
2024
2023
-
PSA reactivity in extracellular microvesicles to commercial immunoassays
Clinica Chimica Acta, Vol. 543
2021
-
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients
Cytokine, Vol. 141
-
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337
2020
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
-
The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients
Disease Markers, Vol. 2019
2018
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
-
Papel de la quimioterapia en el tratamiento del cáncer de próstata metastásico hormonosensible
Archivos Espanoles de Urologia, Vol. 71, Núm. 3, pp. 276-280
2017
-
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
OncoImmunology, Vol. 5, Núm. 1
-
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value
Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694
2015
-
Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica
Anales del sistema sanitario de Navarra, Vol. 38, Núm. 3, pp. 463-464
-
Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient
International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115
2014
-
Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging
-
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
PLoS ONE, Vol. 9, Núm. 1
-
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy
PLoS ONE, Vol. 9, Núm. 2